This is not unusual for proteinaceous solutions. There may be small white particles of protein in the solution. Inspect visually for particulate matter and discoloration prior to administration.
DO NOT remove the needle cover while allowing the prefilled syringe to reach room temperature. Preparation Of Intacept Single-Dose Prefilled Syringeįor a more comfortable injection, leave Intacept prefilled syringes at room temperature for about 15 to 30 minutes before injecting. The Intacept (Intacept) “Instructions for Use” insert for each presentation contains more detailed instructions on injection site selection and the preparation of Intacept. Administer injections subcutaneously in the thigh, abdomen or outer area of the upper arm.
Patients should not self-administer until they receive proper training in how to prepare and administer the correct dose. Patients may self-inject when deemed appropriate and if they receive medical follow-up, as necessary. Intacept is intended for use under the guidance and supervision of a physician.
In JIA patients, glucocorticoids, NSAIDs, or analgesics may be continued during treatment with Intacept. To achieve pediatric doses other than 25 mg or 50 mg, use reconstituted Intacept lyophilized powder.ĭoses of Intacept higher than those described in Table 2 have not been studied in pediatric patients. Dosing and Administration for Pediatric Patients (PsO or JIA) The proportion of responders was related to Intacept dosage. In addition to the 50 mg twice weekly recommended starting dose, starting doses of 25 mg or 50 mg per week were shown to be efficacious. Methotrexate, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with Intacept.īased on a study of 50 mg Intacept twice weekly in patients with RA that suggested higher incidence of adverse reactions but similar American College of Rheumatology (ACR) response rates, doses higher than 50 mg per week are not recommended. Starting Dose: 50 mg twice weekly for 3 monthsĪdult Rheumatoid Arthritis, Ankylosing Spondylitis, And Psoriatic Arthritis Patients Recommended Dosage Strength and Frequency Dosing and Administration for Adult Patients Intacept is administered by subcutaneous injection. Intacept is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Intacept is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Intacept can be used with or without methotrexate.
Intacept is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Intacept is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. Polyarticular Juvenile Idiopathic Arthritis Intacept can be initiated in combination with methotrexate (MTX) or used alone. Intacept is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA).